The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 07, 2021
Filed:
Nov. 17, 2016
Applicant:
The Trustees of Columbia University IN the City of New York, New York, NY (US);
Inventors:
Rebecca Anne Brachman, Westfield, NJ (US);
Christine Ann Denny, New York, NY (US);
René Hen, Tenafly, NJ (US);
Assignee:
The Trustees of Columbia University in the City of New York, New York, NY (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/135 (2006.01); A61P 25/22 (2006.01); A61P 25/24 (2006.01); A61K 9/00 (2006.01); A61K 31/138 (2006.01); A61K 31/401 (2006.01); A61K 31/42 (2006.01); A61K 31/4245 (2006.01); A61K 31/428 (2006.01); A61K 31/4525 (2006.01); A61K 31/453 (2006.01); A61K 31/513 (2006.01); A61K 31/517 (2006.01); A61K 31/53 (2006.01); A61K 33/00 (2006.01); A61K 31/198 (2006.01); A61K 45/06 (2006.01); A61K 31/445 (2006.01);
U.S. Cl.
CPC ...
A61K 31/138 (2013.01); A61K 9/0019 (2013.01); A61K 9/0043 (2013.01); A61K 9/0053 (2013.01); A61K 31/135 (2013.01); A61K 31/198 (2013.01); A61K 31/401 (2013.01); A61K 31/42 (2013.01); A61K 31/428 (2013.01); A61K 31/4245 (2013.01); A61K 31/445 (2013.01); A61K 31/453 (2013.01); A61K 31/4525 (2013.01); A61K 31/513 (2013.01); A61K 31/517 (2013.01); A61K 31/53 (2013.01); A61K 33/00 (2013.01); A61K 45/06 (2013.01); A61P 25/22 (2018.01); A61P 25/24 (2018.01); A61K 2300/00 (2013.01);
Abstract
Methods for prophylactically treating a stress-induced affective disorder or stress-induced psychopathology in a subject are provided. Also provided are methods for inducing and/or enhancing stress resilience in a subject. In certain embodiments, an effective amount, of an antagonist of the glutamate N-methyl-D-aspartate (NMDA) receptor, such as ketamine, or a pharmaceutically acceptable salt or derivative thereof, is administered to a subject prior to a stressor.